Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
The following is a guest post from MEASURE Evaluation and Department of Public Policy, University of North Carolina at Chapel Hill By Paul Brodish An Association […]
In a prospective autopsy study published in The Lancet of patients who died at a hospital in Lusaka, Zambia, researchers found a large percentage of patients […]
Study highlights need to test patients for antiretroviral resistance in resource-limited settings as well as in wealthy ones
Study also finds HIV subtype most common in Africa progresses the fastest A multinational study has spelled out two ways the cards are stacked against those […]
President Obama today nominated a member of his administration whose leadership of health and humanitarian responses included guiding development of the U.S. Global Health Initiative and […]